HIV

Women living with HIV can reduce their risk of cervical cancer using a human papillomavirus (HPV) vaccine that is both cost-effective and effective in preventing the virus.

An update from the PURPOSE 2 trial focused on adherence and pharmacokinetics data for lenacapavir, used to prevent HIV.

The combination therapy of bictegravir/emtricitabine/tenofovir (BIC/FTC/TAF) was both tolerable and produced virologic suppression in patients who were presenting late in their HIV infection.

The prevalence of liver steatosis was higher in people living with HIV compared with liver fibrosis, although both liver conditions are prevalent for these individuals.

As part of our coverage of the biennial AIDS conference from the International AIDS Society, we spoke with Madalitso Juwayeyi, program manager at FACT-Malawi, to learn more about her organization and how it strives to serve the sexual and reproductive health needs of adolescent girls and young women in her native Malawi.

Specific subtypes and transmission clusters for HIV could require targeted interventions to control spread of HIV that is drug-resistant.

People living with HIV (PWH) can have mental health implications related to their neighborhood markers and environment.

Treatment effectiveness and safety can be affected by drug-related problems in patients who experience HIV treatment failure.

Patients living with HIV in Barcelona, Spain have seen a decrease in mortality of patients in critically ill condition admitted to the intensive care unit (ICU).

New data from the PURPOSE 2 trial continue to show the efficacy of lenacapavir in HIV prevention in individuals who have sex with men.

A phase 3b study found that Black individuals who switched to bictegravir/emtricitabine/tenofovir alafenamide were able to maintain virologic suppression after 72 weeks.

The start of AIDS Awareness Month puts a spotlight on how treatment for HIV and AIDS has progressed over the past 40 years.

The legacy of redlining continues to harm minority health, with Black individuals facing higher rates of health issues, linked to environmental factors and limited access to resources in regions previously redlined.

The 25th International AIDS Conference took place July 22-26 in Munich, Germany, and one of the sessions delved into the potential impact of civil society laws on the 95-95-95 targets as laid out in the UNAIDS Global AIDS Strategy for 2021 to 2026.

Systemic racism, including the practice of redlining, has had an enduring effect on health outcomes in people living with HIV, including time to viral suppression.

Follow-up in men living with HIV who have sex with men should be performed to assess quality of life due to sexual function.

In a session at AIDS 2024, the International AIDS Conference, global leaders and community advocates gathered to discuss why stigma and shame continue to attach themselves to an HIV diagnosis and why policy efforts to overcome both must persist.

Goals including addressing all of hunger and food insecurity, unmet needs for mental health services, and unstable housing or homelessness in people living with HIV are unlikely to meet their 2025 thresholds.

Drug use, participation in exchange sex, and depressive symptoms were all found to be associated with bacterial sexually transmitted infections (STIs) in sexual minority men living with HIV.

There were no significant differences found between people with and without HIV when it came to their periodontal profile.

At the 25th International AIDS Conference, Emmanuel Nazaire Essam, MD, MPH, presented the analysis, "Medicaid Insurance Expansion and Its Association With HIV Outcomes in Nebraska, USA: An Observational Prospective Cohort Study."

A federal judge determined that all people being actively treated for HIV can enlist in the military.

At AIDS 2024 in July, Kelly Dyer, MD, Perelman School of Medicine, presented research findings from an investigation at the intersection of health equity, substance use detox, infectious disease screening, and patient harm reduction.

Jennifer Cocohoba, PharmD, MAS, AAHIVP, University of California, San Francisco, School of Pharmacy, discusses the benefits of pharmacy-administered long-acting injectable antiretroviral therapy for HIV and patient attitudes toward pharmacy-administered treatment.

A trio of posters presented at AIDS 2024, the 25th International AIDS Conference, explored widespread disparities in access to pre-exposure prophylaxis (PrEP) and how to make access more equitable, both globally and locally.